Eczema Clinical Research Studies

Atopic dermatitis, or eczema, is the most common chronic inflammatory, pruritic skin disease. It causes intense itching and scratching which leads to a severe rash. Recent eczema studies have given researchers more information about this disease, which is leading to a better understanding of the ailment and new treatment options. There are currently a variety of eczema studies available at our center for patients with mild to severe atopic dermatitis. These studies include treatments such as biologics (complicated molecules that are manufactured within a living organism), a topical gel, and an oral medication designed to help decrease extremely itchy skin involved with eczema. These study medications are at the forefront of current medicine and are provided at absolutely no cost, and with no insurance needed. You may also be reimbursed for your time and travel and will receive care from a physician affiliated with the Clinical Research Center of Alabama.
For more information on any of the following eczema clinical research studies, please contact Will O’Donnell by calling 205.209.4179 or emailing wodonnell@alabamaallergy.com

Biologic Injection Study

Ages 6 months-6 years

Rengeneron 1539

A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of Dupilumab in patients aged ≥6 months to < 6years with severe atopic dermatitis.

ORAL MEDICATION STUDY

Age 19+

Innovaderm

The main purpose of this study is to see if difelikeafalin oral tablets (taken by mouth) can reduce the intensity of itching and whether it is well tolerated in subjects with atopic dermatitis and moderate to severe pruritus. Atopic dermatitis is commonly known as eczema, pruritus is commonly known as itchy skin.

Oral Medication - Add-On Therapy

Age 12-17

AbbVie047

The purpose of this study is to compare the effectiveness and safety of upadacitinib (ABT-494) to placebo (pill without any active substance that looks like upadacitinib) in combination with topical corticosteroids for adolescents (12-17 years of age) with moderate to severe atopic dermatitis (AD).

Oral Medication

Age 19-70

Vanda

The purpose of this study is to evaluate the effect of an investigational drug called Tradipitant on symptoms associated with atopic dermatitis with atopic dermatitis and to assess the safety of Tradipitant.

Oral Medication compared to Biologic

Ages 19+

Pfizer1050

The main purpose of this study is to determine if Abrocitinib (oral medication) is effective and safe at treating symptoms of eczema compared to Dupilumab (biologic). These medications are designed to treat itching, redness, oozing, dryness, and thickening of the skin.

Oral Medication Compared To Dupilumab (Dupixent)

Age 19-75

Abbvie046
The main purpose of this study is to compare the effectiveness and safety of Upadacitinib (ABT-494) versus dupilumab for the treatment of adult subjects with moderate to severe atopic dermatitis who are candidates for systemic therapy.

Biologic Injection Study

Ages 19-75

MedImmune-AZ AD
The purpose of this study is to assess the effectiveness and safety of the study medication MEDI3506 compared with placebo for the treatment of moderate-to-severe atopic dermatitis in adults.

Biologic Injection Study

Ages 12+

Galderma AD
The purpose of this study is to assess the efficacy and safety of the study medication Nemolizumab in adolescent and adult patients with moderate to severe atopic dermatitis.

Biologic Injection Study

Ages 12+

Regeneron1924
The purpose of this study is to determine if the biologic medication, Dupixent, is effective in treating moderate-to-severe atopic hand and foot dermatitis that has been inadequately responsive to high potency topical steroids.

Become a Participant in our Eczema Studies

If you’re interested in participating in a clinical research study at the Clinical Research Center of Alabama, call 205.209.4100 to speak with an experienced coordinator or fill out the contact form below.